J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Devineni, D.
Right arrow Articles by Leung, A. T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Devineni, D.
Right arrow Articles by Leung, A. T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetics and Pharmacodynamics of a Transdermal Contraceptive Patch and an Oral Contraceptive

Damayanthi Devineni, PhD, Donna Skee, BSc, Nicole Vaccaro, BSc, Joseph Massarella, PhD, Luc Janssens, MSc, Katherine D. LaGuardia, MD, MPH and Albert T. Leung, MD, PhD

From Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey (Dr Devineni, Ms Skee, Ms Vaccaro, Dr Massarella, Dr Leung); Johnson & Johnson Pharmaceutical Research and Development, LLC, a division of Janssen Pharmaceutica N.V., Beerse, Belgium (Mr Janssens); and Ortho Women's Health and Urology, Raritan, New Jersey (Dr LaGuardia).

This open-label, randomized, 2-way crossover study characterized the pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and a norgestimate-containing oral contraceptive. Healthy women (n = 34) applied a patch once weekly for 3 consecutive weeks during each of 2 cycles and received an oral contraceptive for 21 consecutive days during each of 2 cycles. Plasma concentrations of norelgestromin and ethinyl estradiol peaked and waned after daily oral contraceptive administration, whereas they rose and reached steady-state levels after first patch application. Norelgestromin exposure was similar; ethinyl estradiol exposure was higher for the patch than oral contraceptive. Hepatic estrogenic activity, assessed by hepatic globulin synthesis, was similar for corticosteroid-binding globulin and corticosteroid-binding globulin-binding capacity and higher for sex hormone–binding globulin for the patch versus oral contraceptive. The clinical significance of the differences in pharmacokinetic and pharmacodynamic profiles between the patch and oral contraceptive is not fully known. No serious adverse events or discontinuations due to adverse events were recorded.

Key Words: Oral contraceptive • transdermal contraceptive patch • ethinyl estradiol • norelgestromin • pharmacokinetics

Address for reprints: Damayanthi Devineni, PhD, Johnson & Johnson Pharmaceutical Research and Development, LLC, 920 Route 202 South, Raritan, NJ 08869; e-mail: ddevinen{at}prdus.jnj.com.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology